Vera Therapeutics (VERA) Interest Expenses (2020 - 2026)

Vera Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $169.5 million for Q1 2026.

• Quarterly Interest Expenses rose 1354.32% year-over-year to $169.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.5 million (up 330.69% YoY) and the FY2025 annual result came in at $260.7 million, up 51.01% from the prior year.
• Interest Expenses was $169.5 million for Q1 2026 at Vera Therapeutics, up from $5.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $169.5 million in Q1 2026 and bottomed at $502000.0 in Q4 2022.
• A 5-year average of $16.6 million and a median of $7.8 million in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 2685.86% in 2023, while the deepest fall reached 85.23% in 2023.
• Vera Therapeutics' Interest Expenses stood at $502000.0 in 2022, then jumped by 2685.86% to $14.0 million in 2023, then sank by 44.1% to $7.8 million in 2024, then slumped by 30.46% to $5.4 million in 2025, then surged by 3017.59% to $169.5 million in 2026.
• Business Quant data shows VERA's Interest Expenses at $169.5 million in Q1 2026, $5.4 million in Q4 2025, and $3.2 million in Q3 2025.